Arthritis, Psoriatic, Psoriasis
Conditions
Brief summary
Anti-carbamylated protein (anti-CarP) antibodies are present in approximately one-fourth of the patients who are seronegative for both rheumatoid factor and anti-citrullinated protein antibody and who may therefore have psoriatic arthritis. The investigators hypothesized that detection of anti-CarP antibodies in serum may be useful for diagnosis of psoriatic arthritis.
Interventions
DIAGNOSTIC_TESTSerum anti-CarP antibodies detection
Serum anti-CarP antibodies detection using an enzyme-linked immunosorbent assay (ELISA) from Inova Diagnostics.
Sponsors
Association pour la Recherche Clinique et Immunologique
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Controls : Patients with a psoriasis confirmed by a dermatologist and with absence of psoriatic arthritis confirmed by a rheumatologist. * Cases : Patients with psoriatic arthritis fulfilling the classification criteria for psoriatic arthritis (CASPAR), with a diagnosis confirmed by a rheumatologist and associated with personal or familial psoriasis.
Exclusion criteria
* Controls: Presence of any chronic rheumatic inflammatory disease such as psoriatic arthritis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensitivity of anti-carbamylated protein antibodies for the diagnosis of psoriatic arthritis in the psoriatic population | Anti-CarP antibodies will be assessed in the sera collected at the recruitment visit |
Countries
France
Outcome results
None listed